Navigation Links
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
Date:2/26/2009

rporation. Based on InterMune's ownership of approximately 3 million Targanta shares, InterMune expects to receive approximately $6.0 million in the current quarter as a result of the transaction.

2009 Key Project Guidance

The company provided guidance on its key development projects, pirfenidone and ITMN-191.

Pirfenidone

The company plans to submit an NDA to the FDA and an MAA to the EMEA on pirfenidone in the summer of 2009 and around the end of 2009, respectively.

2009 ITMN-191 Clinical Development Plans and Timeline

InterMune provided an update on the development plan and key milestones for its protease inhibitor ITMN-191, being developed in collaboration with Roche as follows:

    ITMN-191 MILESTONES AND KEY EVENTS                       EXPECTED DATE
    -- Scientific presentation of Phase 1b triple
       combination study                                     Q2, 2009 (EASL)
    -- Top-line results of INFORM-1 STAT-C study at EASL     Q2, 2009 *
    -- Phase 2b initiation by Roche
       ($20 million payment to InterMune)                    Summer 2009
    -- Presentation of all cohorts of INFORM-1 at AASLD      Q4, 2009 *
    -- Rapid Viral Response (RVR) data from Phase 2b
       (12-week regimen)                                     Q4 '09 or Q1 '10

    * Subject to acceptance of scientific abstract


    Guidance for 2009 Revenue and Expenses

Revenue

Revenue for 2009, including Actimmune(R) and anticipated milestone payments from Roche, is expected to be in a range of approximately $40 to $50 million. Actimmune revenue represents approximately 50% of this revenue range.

Operating Expenses

R&D expense is anticipated to be in a range of approximately $90 to $100 million, net of development cost reimbursements under the Roche collaboration. Of
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
2. InterMune Announces Issuance of U.S. Patent for ITMN-191
3. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
4. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune to Present at Deutsche Bank Biotech Boston Confab
7. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
8. InterMune to Release Third Quarter 2008 Financial Results on November 6
9. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
10. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
11. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... MD (PRWEB) May 23, 2013 Can ... off from work motivate members of the public to ... researchers including Johns Hopkins Carey Business School ... emphatic yes. Pointing to a large body of recent ... in the May 24, 2013, issue of Science that ...
(Date:5/23/2013)... PuraMed BioScience ® , Inc., (OTCBB: ... (OTC) medicinal and healthcare products, announced that Ludlow ... based on low market capitalization valuation. ... Product to Treat Migraine Headaches , Clinical ... , Currently Available Nationwide at Walgreen,s and ...
(Date:5/23/2013)... 23, 2013 PI’s new LPS-24 ... provide 15 mm travel range with closed-loop sensor ... dimensions make these new positioners the ideal choice ... vacuum rated version is also available. , ... datasheets can be found at: , http://www.physikinstrumente.com/en/products/prdetail.php?sortnr=1000745&prw-lps24 ...
(Date:5/23/2013)... 23, 2013 Virobay, Inc. today announced that ... reached an important milestone, as Virobay has now initiated ... selective cathepsin S inhibitor.   The first ... placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics ... adults. "The initiation of this Phase 1 ...
Breaking Biology Technology:Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
... six Wisconsin biotech companies will present at an upcoming ... another signal of the rising influence of regional gatherings ... travel to Minneapolis for the Sept. 21-23 BIO ... Organization . Companies will present business plans and technology ...
... publication DM Review based in Wisconsin, announced ... competition. , ,The award, a symbol of excellence within ... given out since 1996. Entries are accepted in categories ... by feedback from DM Review readers. , ,Winners will ...
... Wis. - The Center for Technology Transfer ... LLC, a company that has developed a series of ... reduce usage of natural gas in their furnaces. , ,The ... will help Spinworks expand its business and product offerings, the ...
Cached Biology Technology:Six Wisconsin firms to present at BIO Mid-America VentureForum 2Six Wisconsin firms to present at BIO Mid-America VentureForum 3DM Review announces award finalists 2Tech center supports energy-saving device for heat-treating plants 2
(Date:5/22/2013)... (May 22, 2013)The omega 3 fatty acids in fish ... diseaseso much so that the American Heart Association currently ... week, particularly fatty varieties rich in omega 3s. However, ... mystery. In a new study, scientists led by Jason ... this phenomenon by providing evidence that fish oil might ...
(Date:5/22/2013)... the whole organism, as they may lead to life-threatening ... now report how byproducts of respiration cause mispairing of ... our cells controls the form and function of every ... are encoded in the linear sequence of the four ... (C), guanine (G) and thymine (T). Random changes in ...
(Date:5/22/2013)... Irvine, Calif., May 22, 2013 Early screening for ... personal pregnancy testing is for women, thanks to UC ... the American Chemical Society . , After more than ... a way to clearly identify clinically usable markers for ... be detected far sooner, with greater accuracy and at ...
Breaking Biology News(10 mins):Fish oil may help the heart beat mental stress 2DNA damage: The dark side of respiration 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3
... Primate Research Center, Emory University, have successfully generated ... toward unlocking the genetic secrets of pair bonding. ... enable scientists to perform a host of genetic ... of social bonding and other complex social behaviors. ...
... German . , Brown adipose tissue is different from ... stations which among other things can ,burn, fat. In doing this, ... which then provides energy for cellular processes. However, the mitochondria of ... ahead all the time. The energy released when the fat is ...
... the scientists, one from the United States, the other from Canada, ... pack, on remote Ellesmere Island, only 600 miles from the North ... Pole wolves" do in the long, dark days of winter in ... 9-year-old Brutus back in 2003," said David Mech, a renowned U.S. ...
Cached Biology News:Yerkes researchers create first transgenic prairie voles 2Brown fat cells make 'spare tires' shrink 2North Pole wolf emails locations to researchers 2North Pole wolf emails locations to researchers 3
AANAT [Arylalkylamine N-acetyltransferase; EC 2.3.1.87]...
TUP1 Market Segment: Molecular Biology...
NANS Immunogen: NANS (NP_061819, 260 a.a. ~ 360 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
Biology Products: